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Exercise Window Trial in Newly Diagnosed Breast Cancer - Letter 
Andrew H. Sims1, Melanie Leggate2, Anna Campbell2 
1Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research UK Centre, 
Edinburgh, UK 
2
 School of Applied Sciences, Edinburgh Napier University, Edinburgh, UK 
We read with great interest the article by Ligibel and colleagues [1], of the Pre-Operative 
Health and Body (PreHAB) study looking at the molecular effects of exercise on breast 
tumours between diagnosis and surgery. The reported up-regulation of pathways related to 
inflammation and immunity is consistent with the expected role of the tumour 
microenvironment in response to exercise [2]. Sequentially-sampled window studies have 
great potential to inform by minimising patient-patient variation, but are a very challenging 
way to examine the effects of treatment or other interventions. Assessment of proliferation 
is a natural endpoint for response, but measurement of Ki67 is notoriously unreliable.  
There are many different gene expression analysis approaches and numerous breast cancer 
signatures [3]. The current drive for reproducible research has led to expectations that 
datasets and analysis software are made freely available. With this in mind and our desire to 
perform similar studies, we reanalysed the PreHAB study gene expression data (GSE129508) 
using the GeneFu package [4] to calculate estimations of the established genomic grade 
index, PAM50 and Mammaprint risk of relapse prognosis prediction algorithms of the 
samples taken at diagnosis and excision from patients randomised to the exercise and 
control groups. 
The majority of exercising patients (12/16) had significantly reduced predicted PAM50 risk 
of relapse scores (p=0.03), whereas half of the control group had smaller non-significant 
(p=0.81) reductions in predicted risk of relapse. Trends (p=0.08, p=0.09) for reductions in 
genomic grade index and Mammaprint scores in most exercising patients were not evident 
in controls (Figure 1). These prognostic signatures were derived from different analytical 
approaches and represent different facets of breast tumour biology including proliferation, 
immune response and oestrogen signalling.  
Whole tumour gene expression profiling captures information on all cell types, whereas 
deconvolution approaches can generate in silico predictions of the proportions of immune 
cell types present in samples. As above, we used the ImSig package [5] to assess changes in 
immune cell content changes in the PreHAB data. Increases in several immune cell types 
were observed including macrophages and B-cells, alongside a reduction in proliferation, 
but these changes were not statistically significant.  
Our analysis highlights different analysis approaches and supports the findings of the 
original study. We strongly encourage further studies in this area to examine the biological 
consequences of exercise on tumours along with assessments of the feasibility of 
introducing optimal and tolerable exercise regimens into routine clinical care for cancer 
patients. 
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Figure 1 Pre-surgical exercise improves predicted prognosis for breast cancer patients 
Reductions in molecular signature scores are shown in blue and increases in red.  
 
